| Filed On | Filing |
|---|---|
| 06 Nov 2026 |
8-K: Other Events
Pulse Biosciences Presents Six-Month Interim Results from the PRECISE-BTN Multicenter Study at the American Thyroid Association Annual Meeting |
| 05 Nov 2026 | FORM 10-Q |
| 05 Nov 2026 |
8-K: Results of Operations and Financial Condition
Completed enrollment of NANOPULSE-AF US IDE pivotal study for treatment of AF with nPulse Cardiac Catheter System |
| 14 Oct 2026 |
8-K: Other Events
Collaboration adds the nPulse™ Vybrance™ System to patient care at the Hospital for Endocrine Surgery and supports generation of additional clinical data |
| 07 Oct 2026 |
8-K: Other Events
Pulse Biosciences Achieves Enrollment Target in NANOPULSE-AF IDE Pivotal Clinical Study Evaluating nPulse™ Cardiac Catheter System for Atrial Fibrillation Treatment |
| 15 Sep 2026 |
8-K: Entry into a Material Definitive Agreement; Termination of a Material Definitive Agreement
Pulse Biosciences, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time to or through Mizuho Securities USA LLC (the “Agent”), as sales agent, shar... |
| 15 Sep 2026 | FORM 424B5 |
| 15 Sep 2026 |
8-K: Other Events
Pulse Biosciences Completes Enrollment in the PRECISE-BTN Clinical Study Evaluating the nPulse™ Vybrance™ Percutaneous Electrode System for Symptomatic Benign Thyroid Nodules |
| 02 Sep 2026 |
Form 4: Teplitsky Liane Rae, Chief Operating Officer
Bought 1,024 shares ($50K) · Bought 1,001 shares ($50K) |
| 28 Aug 2026 |
Form 4: Teplitsky Liane Rae, Chief Operating Officer
Bought 1,036 shares ($50K) · Bought 1,034 shares ($50K) |
| 28 Aug 2026 |
Form 4: Teplitsky Liane Rae, Chief Operating Officer
Granted 200,000 Restricted Stock Units · Granted 700,000 Stock Option (right to buy) |
| 28 Aug 2026 |
Form 3: Teplitsky Liane Rae, Chief Operating Officer
No securities owned |
| 28 Aug 2026 |
Form 4: Skinner Jon, Chief Financial Officer
Granted 300,000 Stock Option (right to buy) |
| 28 Aug 2026 |
Form 3: Skinner Jon, Chief Financial Officer
No securities owned |
| 06 Aug 2026 |
8-K: Entry into a Material Definitive Agreement
Pulse Biosciences, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time to or through Mizuho Securities USA LLC (the “Agent”), as sales agent, shar... |
| 06 Aug 2026 | FORM 424B5 |
| 06 Aug 2026 | FORM 10-Q |
| 06 Aug 2026 |
8-K: Results of Operations and Financial Condition
HAYWARD, California [Business Wire] — August 6, 2026. Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced business upda... |
| 29 Jul 2026 |
8-K: Other Events
HAYWARD, California, July 29, 2026 – Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced that the NANOPULSE-AF Study ha... |
| 15 Jun 2026 |
Form 4: Zanganeh Mahkam, Director
Granted 44,504 Stock Option (right to buy) |
Loading...